N/A N=64 A Trial of Vitamin D Therapy in Patients With Heart Failure
Heart Failure
Primary: Peak VO2 — -.17; -.68 ml/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Breast Cancer · Cancer
Primary: The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase — 0; 2; 0 Participants
N/A N=72 mHealth for Self-care of Heart Failure in Uganda
Heart Failure
Primary: Self-Care for Heart Failure Index, Maintenance — 35; 85 score on a scale — p=<0.001
Phase 3 N=55 Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
Overweight and Obesity · Eating Behavior
Primary: Ad Libitum Food and Beverage Intake (g) — 71.5; 81.9; 24.9; 33.6 g — p=0.45
N/A N=41 Soccer-based Adaptation of the Diabetes Prevention Program
Diabetes
Primary: Number of Participants Completing the Study — 25 Participants
N/A N=99 A Trial of Telemonitoring in Adults With Heart Failure
Heart Failure
Primary: The Amount of Time Participants Are Readmitted to the Hospital or Visit the Emergency Department (ED). — 60; 62 Days
Phase 2 N=12 Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury
Spinal Cord Injuries
Primary: 10 Meter Walk Time — -5.0; -4.9; -4.6; -5.5 Seconds
Phase 2 N=48 NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Neurofibromatosis 1 · Cutaneous Neurofibroma
Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…
Phase 3 N=538 A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee
Osteoarthritis of the Knee
Primary: Change in WOMAC A Pain — -0.81; -0.81 score on a scale — p=0.97
Phase 2 N=46 High Dose Vitamin D for Sickle Cell Disease
Sickle Cell Disease
Primary: 25 (OH)D in Nmol/L Between Baseline and 6 Months — 55.2; 50.4 nmol/L — p=0.0507
N/A N=124 Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
NASH - Nonalcoholic Steatohepatitis
Primary: Percent Change in MBT From Day 1 to Week 48 — 8.8; 12.3; -4.7; 15.3 percentage of change in MBT
Phase 2 N=97 Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months — -0.04; -0.11 score on a scale — p=0.50
N/A N=15 Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
Prostate Adenocarcinoma
Primary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants
N/A N=7 Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")
Diabetes Mellitus, Type 1 · Type 1 Diabetes
Primary: The Primary Endpoint is the Rate of Decline (s) Over Wear Time (DOI, Day 3, Day 5, Day 7) of the Natural Logarithm of the Area Under the Glucose Infusion Rate Curve [ln…
Phase 1 N=26 Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults
HIV-1 Infection
Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 43; 14; 0; 0 percentage of participants